Mutant CYAA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell.

0465755 - MBÚ 2017 RIV eng P - Patentový dokument
Šebo, Peter - Osičková, Adriana - Mašín, Jiří - Fayolle, C. - Krůšek, Jan - Basler, Marek - Leclerc, C. - Osička, Radim
Mutant CYAA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell.
2015. Vlastník: Institut Pasteur (FR)- Fyziologický ústav AV ČR,v. v. i.- Mikrobiologický ústav AV ČR, v. v. i. Datum udělení patentu: 29.12.2015. Číslo patentu: US9222143
Grant CEP: GA MŠMT 2B06161; GA AV ČR IAA500200914
Institucionální podpora: RVO:61388971 ; RVO:67985823
Klíčová slova: bordetella pertussis * pertussis * antigen delivery
Kód oboru RIV: EE - Mikrobiologie, virologie; ED - Fyziologie (FGU-C)
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=9,222,143.PN.&OS=PN/9,222,143&RS=PN/9,222,143

The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. Said mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermore have a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.


Trvalý link: http://hdl.handle.net/11104/0264298